In addition, the combination of tubulin inhibitor VERU-111 and vemurafenib also inhibited vemurafenib-resistant melanoma effectively by inhibiting tubulin protein and Skp2 protein together (Cui et al., 2021). Here, SKP2 is linked to melanoma.